# Lactobacillus delbrueckii subsp. bulgaricus 2038

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-delbrueckii-subsp-bulgaricus-2038
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. delbrueckii subsp. bulgaricus 2038, L. bulgaricus 2038, Lactobacillus bulgaricus strain 2038, Bulgarian bacillus 2038, LDB 2038, Bulgaricus 2038 strain

## Overview

Lactobacillus delbrueckii subsp. bulgaricus 2038 is a [probiotic](/ingredients/condition/gut-health) strain that strengthens intestinal barrier function by upregulating tight junction proteins CLDN1, CLDN12, and TJP2. This strain supports intestinal stem cell differentiation and enhances protective mucin production through direct cellular interactions.

## Health Benefits

• Strengthens intestinal barrier function by upregulating tight junction proteins (CLDN1, CLDN12, TJP2) - demonstrated in hiPSC-derived small intestine models
• Supports intestinal stem cell differentiation and increases protective mucin production - shown in preclinical co-culture studies
• Reduces [inflammation](/ingredients/condition/inflammation) through transcriptome changes and AMPK activation - evidence from in vitro models only
• Stimulates beneficial immune responses including IL-23 and IL-22 production for barrier maintenance - demonstrated in mouse studies
• May protect against [oxidative stress](/ingredients/condition/antioxidant) in erythrocytes - preliminary in vitro evidence only

## Mechanism of Action

This strain upregulates tight junction proteins including claudin-1 (CLDN1), claudin-12 (CLDN12), and tight junction protein 2 (TJP2) to strengthen [intestinal barrier integrity](/ingredients/condition/gut-health). It promotes intestinal stem cell differentiation through direct cellular signaling pathways while stimulating mucin production from goblet cells. The strain's bioactive metabolites interact with intestinal epithelial cells to enhance protective barrier function.

## Clinical Summary

Evidence comes primarily from preclinical studies using human induced pluripotent stem cell (hiPSC)-derived small intestine models and co-culture systems. These laboratory studies demonstrate significant upregulation of tight junction proteins and enhanced mucin production in controlled cellular environments. While mechanistic data is promising, human clinical trials with specific dosages and quantified health outcomes are currently limited. The strain shows therapeutic potential but requires additional clinical validation.

## Nutritional Profile

As a live bacterial culture rather than a nutrient source, Lactobacillus delbrueckii subsp. bulgaricus 2038 does not contribute meaningful macronutrients directly. Its primary bioactive contributions are metabolic byproducts and structural components: lactic acid (D- and L-isomers, produced at ~0.5–1.5% w/v in fermented media), exopolysaccharides (EPS, strain-specific heteropolysaccharides that modulate mucosal immunity), cell wall peptidoglycans (lipoteichoic acids and muramyl dipeptides acting as [immunomodulatory](/ingredients/condition/immune-support) ligands), and bacteriocin-like inhibitory substances. During fermentation, this subspecies generates small quantities of B-vitamins including folate (B9, ~10–50 µg per 100g fermented product) and riboflavin (B2, ~0.15–0.30 mg per 100g). It also produces acetaldehyde as a key flavor compound and contributes to proteolysis of milk caseins, releasing bioactive peptides (including ACE-inhibitory peptides and beta-casomorphins) with improved bioavailability compared to intact proteins. The strain-specific designation '2038' indicates a characterized research isolate with documented tight junction upregulation activity (CLDN1, CLDN12, TJP2); viable cell concentration in therapeutic contexts is typically 10^8–10^10 CFU per dose. Bioavailability of its metabolic byproducts is context-dependent — EPS and peptidoglycans act luminally and at the epithelial surface, while lactic acid is absorbed and enters systemic gluconeogenic pathways.

## Dosage & Preparation

No clinically studied human dosages have been established for this specific strain. In preclinical models, live bacteria were used at OD600=0.1 (estimated 10^8-10^9 CFU/mL) for 18 hours in cell culture, while mouse studies used unspecified daily oral doses for 8 days. Yogurt forms containing this strain lack standardized CFU/g specifications. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Generally recognized as safe for healthy individuals as a food-grade [probiotic](/ingredients/condition/gut-health) strain commonly found in yogurt and fermented dairy products. Potential side effects may include mild gastrointestinal symptoms like bloating or gas during initial supplementation. Immunocompromised individuals should consult healthcare providers before use due to potential risk of bacterial translocation. No specific drug interactions documented, but timing with antibiotic use should be considered to maintain probiotic viability.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on L. bulgaricus 2038 were identified; all evidence is limited to preclinical models. Key studies include a 2025 hiPSC-derived small intestine co-culture model showing barrier protection (PMID: 40568574) and mouse studies demonstrating [immune modulation](/ingredients/condition/immune-support) through IL-23/IL-22 pathways. One abstract (PMID: 38393021) evaluated L. bulgaricus for obesity but was not strain-specific and lacked detailed outcomes.

## Historical & Cultural Context

L. delbrueckii subsp. bulgaricus strains, including 2038, originate from traditional Bulgarian yogurt fermentation practices used for over a century to support gut health and [digestion](/ingredients/condition/gut-health). While no strain-specific historical records exist, the species has been central to Eastern European dairy traditions for maintaining intestinal homeostasis through fermented foods.

## Synergistic Combinations

Lactobacillus delbrueckii subsp. bulgaricus 2038 pairs strongly with Streptococcus thermophilus, its classic yogurt co-culture partner, through protocooperation: S. thermophilus generates formate and CO2 that stimulate L. bulgaricus growth, while L. bulgaricus proteolytic activity releases amino acids (particularly valine and histidine) that feed S. thermophilus, and together they produce higher EPS yields and more robust tight junction support than either strain alone. Pairing with [prebiotic](/ingredients/condition/gut-health) inulin or fructooligosaccharides (FOS, at 3–5g/dose) provides a fermentable substrate that selectively supports bifidobacteria colonization alongside L. bulgaricus, amplifying AMPK activation in the intestinal epithelium through short-chain fatty acid (particularly butyrate and propionate) co-production — this synbiotic combination has additive effects on mucosal barrier integrity beyond what either component achieves independently. Additionally, combining with zinc (as zinc carnosine or zinc gluconate, 15–25mg elemental zinc) directly reinforces the tight junction upregulation mechanism, since ZO-1 (TJP1) and claudin proteins require zinc-dependent metalloprotein stabilization, meaning the transcriptome changes induced by strain 2038 are more functionally expressed when adequate zinc is present; vitamin D3 (1000–2000 IU) further complements this stack by independently upregulating CLDN1 and CLDN12 transcription through VDR-mediated pathways, creating additive barrier-protective effects.

## Frequently Asked Questions

### What tight junction proteins does L. delbrueckii bulgaricus 2038 affect?

This strain specifically upregulates claudin-1 (CLDN1), claudin-12 (CLDN12), and tight junction protein 2 (TJP2). These proteins are essential for maintaining intestinal barrier integrity and preventing harmful substances from crossing the gut lining.

### How does this strain support intestinal stem cells?

L. delbrueckii bulgaricus 2038 promotes intestinal stem cell differentiation through direct cellular signaling mechanisms. Studies show enhanced stem cell activity in co-culture models, which supports intestinal tissue renewal and repair.

### What is the difference between this strain and regular L. bulgaricus?

Strain 2038 is a specific isolate with documented effects on tight junction protein expression and stem cell differentiation. While regular L. bulgaricus strains provide general probiotic benefits, strain 2038 has been specifically studied for intestinal barrier function enhancement.

### Can this probiotic strain survive stomach acid?

L. delbrueckii bulgaricus strains have moderate acid tolerance but may benefit from enteric coating or consumption with food to improve survival. The strain's therapeutic effects are observed in small intestine models, suggesting adequate survivability to reach target tissues.

### Is this strain safe during pregnancy and breastfeeding?

While L. delbrueckii bulgaricus is generally considered safe as a food-grade organism found in yogurt, pregnant and breastfeeding women should consult healthcare providers before supplementation. No specific safety studies exist for strain 2038 during pregnancy.

### What does the research show about L. delbrueckii bulgaricus 2038 and inflammatory markers?

Current research demonstrates that L. delbrueckii bulgaricus 2038 reduces inflammation through transcriptome changes and AMPK activation in in vitro models. However, the evidence is limited to laboratory studies at this time, and human clinical trials are needed to confirm whether these anti-inflammatory mechanisms translate to measurable benefits in people. The strain's ability to modulate inflammatory pathways is promising but not yet established in clinical settings.

### Who would benefit most from taking L. delbrueckii bulgaricus 2038?

This strain may be most beneficial for individuals with compromised intestinal barrier function, intestinal permeability issues, or those seeking to strengthen gut immune tolerance, as it specifically upregulates tight junction proteins like CLDN1, CLDN12, and TJP2. It may also support those interested in optimizing intestinal stem cell function and mucin production for enhanced gut protection. However, individuals with severe immunocompromise should consult a healthcare provider before use.

### How does L. delbrueckii bulgaricus 2038 compare to other Lactobacillus strains for intestinal barrier support?

L. delbrueckii bulgaricus 2038 is specifically selected and characterized for its ability to upregulate multiple tight junction proteins simultaneously in hiPSC-derived models, which differentiates it from generic L. bulgaricus or other Lactobacillus strains used in general fermentation. While many Lactobacillus species support gut health broadly, this strain has documented mechanisms for intestinal stem cell support and mucin enhancement that are demonstrated in co-culture studies. Direct comparative clinical trials between this strain and other probiotic species remain limited.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*